These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20842278)

  • 1. Do Hospital and Community SSRI Usage Patterns in Children and Adolescents Match the Evidence?
    Ronsley R; Elbe D; Smith DH; Garland EJ
    J Can Acad Child Adolesc Psychiatry; 2010 Aug; 19(3):218-26. PubMed ID: 20842278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
    Lam D; Gorman DA; Patten S; Pringsheim T
    Paediatr Drugs; 2013 Aug; 15(4):319-27. PubMed ID: 23529865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK.
    Murray ML; Thompson M; Santosh PJ; Wong IC
    Drug Saf; 2005; 28(12):1151-7. PubMed ID: 16329717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
    Womersley K; Ripullone K; Agius M
    Psychiatr Danub; 2017 Sep; 29(Suppl 3):629-644. PubMed ID: 28953843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low SSRI dosing in clinical practice-a register-based longitudinal study.
    Lisinski A; Hieronymus F; Eriksson E; Wallerstedt SM
    Acta Psychiatr Scand; 2021 May; 143(5):434-443. PubMed ID: 33404081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents.
    Hosenbocus S; Chahal R
    J Can Acad Child Adolesc Psychiatry; 2011 Feb; 20(1):60-7. PubMed ID: 21286371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis.
    Ma D; Zhang Z; Zhang X; Li L
    Curr Med Res Opin; 2014 Jun; 30(6):971-95. PubMed ID: 24188102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danish physicians' preferences for prescribing escitalopram over citalopram and sertraline to treatment-naïve patients: a national, register-based study.
    Poulsen KK; Glintborg D; Moreno SI; Thirstrup S; Aagaard L; Andersen SE
    Eur J Clin Pharmacol; 2013 May; 69(5):1167-71. PubMed ID: 23128965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.
    Hermann M; Waade RB; Molden E
    Ther Drug Monit; 2015 Aug; 37(4):546-9. PubMed ID: 25565671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.
    Assimon MM; Pun PH; Al-Khatib SM; Brookhart MA; Gaynes BN; Winkelmayer WC; Flythe JE
    Nephrol Dial Transplant; 2022 Oct; 37(11):2241-2252. PubMed ID: 35793567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
    Handley AP; Williams M
    J Am Assoc Nurse Pract; 2015 Jan; 27(1):54-61. PubMed ID: 24944075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A renaissance for fluoxetine in the management of depression in the elderly?
    Guay DR
    Consult Pharm; 2003 Jan; 18(1):51-62. PubMed ID: 16563053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19.
    Sidky H; Sahner DK; Girvin AT; Hotaling N; Michael SG; Gersing K
    medRxiv; 2023 Feb; ():. PubMed ID: 36380766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs).
    Keene MS; Eaddy MT; Mauch RP; Regan TS; Shah M; Chiao E
    Curr Med Res Opin; 2005 Oct; 21(10):1651-8. PubMed ID: 16238905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and tolerability among different selective serotonin re-uptake inhibitors and venlafaxine in a naturalistic setting.
    Arias F; Padín JJ; Gilaberte I; Varillas P; Sánchez R; Gómez S; García D
    Int J Psychiatry Clin Pract; 1998; 2(4):255-60. PubMed ID: 24927088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogenic/antiestrogenic activity of selected selective serotonin reuptake inhibitors.
    Pop A; Lupu DI; Cherfan J; Kiss B; Loghin F
    Clujul Med; 2015; 88(3):381-5. PubMed ID: 26609273
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.